Cost‐utility analysis of emicizumab prophylaxis in haemophilia A patients with factor VIII inhibitors in Korea

H Lee, H Cho, JW Han, AY Kim, S Park, M Lee… - …, 2021 - Wiley Online Library
Aims Haemophilia A patients with factor VIII inhibitors (HAPI) experience frequent
spontaneous bleeding, approximately once a week, and require expensive bypassing agent …
被引用次数：22 相关文章

Cost-utility analysis of emicizumab prophylaxis in haemophilia A patients with factor VIII inhibitors in Korea

H Lee, H Cho, JW Han, AY Kim… - … : the official journal …, 2021 - pubmed.ncbi.nlm.nih.gov
Aims Haemophilia A patients with factor VIII inhibitors (HAPI) experience frequent
spontaneous bleeding, approximately once a week, and require expensive bypassing agent …

Cost‐utility analysis of emicizumab prophylaxis in haemophilia A patients with factor VIII inhibitors in Korea.

H Lee, H Cho, JW Han, AY Kim, S Park, M Lee… - …, 2021 - search.ebscohost.com
Aims: Haemophilia A patients with factor VIII inhibitors (HAPI) experience frequent
spontaneous bleeding, approximately once a week, and require expensive bypassing agent …

Cost-utility analysis of emicizumab prophylaxis in haemophilia A patients with factor VIII inhibitors in Korea.

H Lee, H Cho, JW Han, AY Kim, S Park… - … : the Official Journal of …, 2020 - europepmc.org
Aims Haemophilia A patients with factor VIII inhibitors (HAPI) experience frequent
spontaneous bleeding, approximately once a week, and require expensive bypassing agent …

Cost-utility analysis of emicizumab prophylaxis in haemophilia A patients with factor VIII inhibitors in Korea

H Lee, H Cho, JW Han, AY Kim, S Park… - …, 2021 - yonsei.elsevierpure.com
Aims: Haemophilia A patients with factor VIII inhibitors (HAPI) experience frequent
spontaneous bleeding, approximately once a week, and require expensive bypassing agent …